INCYTE CORP (INCY) Stock Fundamental Analysis

NASDAQ:INCY • US45337C1027

101.1 USD
+0.35 (+0.35%)
At close: Feb 13, 2026
98.64 USD
-2.46 (-2.43%)
After Hours: 2/13/2026, 8:17:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Taking everything into account, INCY scores 6 out of 10 in our fundamental rating. INCY was compared to 523 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making INCY a very profitable company, without any liquidiy or solvency issues. INCY has a bad growth rate and is valued cheaply. These ratings could make INCY a good candidate for value investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year INCY was profitable.
  • INCY had a positive operating cash flow in the past year.
  • INCY had positive earnings in 4 of the past 5 years.
  • Of the past 5 years INCY 4 years had a positive operating cash flow.
INCY Yearly Net Income VS EBIT VS OCF VS FCFINCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

  • The Return On Assets of INCY (18.78%) is better than 96.75% of its industry peers.
  • With an excellent Return On Equity value of 25.55%, INCY belongs to the best of the industry, outperforming 96.75% of the companies in the same industry.
  • INCY's Return On Invested Capital of 19.88% is amongst the best of the industry. INCY outperforms 97.71% of its industry peers.
  • INCY had an Average Return On Invested Capital over the past 3 years of 7.24%. This is significantly below the industry average of 18.27%.
  • The 3 year average ROIC (7.24%) for INCY is below the current ROIC(19.88%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 18.78%
ROE 25.55%
ROIC 19.88%
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
INCY Yearly ROA, ROE, ROICINCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • The Profit Margin of INCY (24.69%) is better than 94.84% of its industry peers.
  • INCY's Profit Margin has declined in the last couple of years.
  • INCY's Operating Margin of 26.10% is amongst the best of the industry. INCY outperforms 95.79% of its industry peers.
  • In the last couple of years the Operating Margin of INCY has declined.
  • INCY's Gross Margin of 93.47% is amongst the best of the industry. INCY outperforms 94.46% of its industry peers.
  • In the last couple of years the Gross Margin of INCY has remained more or less at the same level.
Industry RankSector Rank
OM 26.1%
PM (TTM) 24.69%
GM 93.47%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
INCY Yearly Profit, Operating, Gross MarginsINCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), INCY is creating some value.
  • There is no outstanding debt for INCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INCY Yearly Shares OutstandingINCY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
INCY Yearly Total Debt VS Total AssetsINCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 9.02 indicates that INCY is not in any danger for bankruptcy at the moment.
  • INCY has a Altman-Z score of 9.02. This is amongst the best in the industry. INCY outperforms 80.50% of its industry peers.
  • INCY has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
  • INCY has a Debt to FCF ratio of 0.03. This is amongst the best in the industry. INCY outperforms 96.37% of its industry peers.
  • INCY has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • INCY's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. INCY outperforms 45.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 9.02
ROIC/WACC1.62
WACC12.31%
INCY Yearly LT Debt VS Equity VS FCFINCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B 5B

2.3 Liquidity

  • INCY has a Current Ratio of 3.20. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.20, INCY is doing worse than 61.95% of the companies in the same industry.
  • A Quick Ratio of 3.13 indicates that INCY has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.13, INCY is not doing good in the industry: 60.04% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 3.13
INCY Yearly Current Assets VS Current LiabilitesINCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 414.39% over the past year.
  • INCY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.67% yearly.
EPS 1Y (TTM)414.39%
EPS 3Y34.67%
EPS 5YN/A
EPS Q2Q%25.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.84%

3.2 Future

  • The Earnings Per Share is expected to decrease by -7.86% on average over the next years.
  • The Revenue is expected to decrease by -1.16% on average over the next years.
EPS Next Y17.92%
EPS Next 2Y14.96%
EPS Next 3Y14.58%
EPS Next 5Y-7.86%
Revenue Next Year10.92%
Revenue Next 2Y10.4%
Revenue Next 3Y7.93%
Revenue Next 5Y-1.16%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
INCY Yearly Revenue VS EstimatesINCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
INCY Yearly EPS VS EstimatesINCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 14.89 indicates a correct valuation of INCY.
  • 95.98% of the companies in the same industry are more expensive than INCY, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.97. INCY is valued slightly cheaper when compared to this.
  • With a Price/Forward Earnings ratio of 12.63, INCY is valued correctly.
  • 97.71% of the companies in the same industry are more expensive than INCY, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of INCY to the average of the S&P500 Index (27.96), we can say INCY is valued rather cheaply.
Industry RankSector Rank
PE 14.89
Fwd PE 12.63
INCY Price Earnings VS Forward Price EarningsINCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, INCY is valued cheaper than 96.37% of the companies in the same industry.
  • INCY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. INCY is cheaper than 96.37% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.58
EV/EBITDA 12.17
INCY Per share dataINCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • INCY has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as INCY's earnings are expected to grow with 14.58% in the coming years.
PEG (NY)0.83
PEG (5Y)N/A
EPS Next 2Y14.96%
EPS Next 3Y14.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for INCY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INCYTE CORP

NASDAQ:INCY (2/13/2026, 8:17:26 PM)

After market: 98.64 -2.46 (-2.43%)

101.1

+0.35 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10
Earnings (Next)04-27
Inst Owners105.27%
Inst Owner Change-0.92%
Ins Owners0.96%
Ins Owner Change-10.69%
Market Cap19.85B
Revenue(TTM)N/A
Net Income(TTM)1.19B
Analysts75
Price Target104.47 (3.33%)
Short Float %5.62%
Short Ratio5.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.23%
Min EPS beat(2)4.72%
Max EPS beat(2)33.74%
EPS beat(4)3
Avg EPS beat(4)10.09%
Min EPS beat(4)-10.01%
Max EPS beat(4)33.74%
EPS beat(8)3
Avg EPS beat(8)-1.54%
EPS beat(12)6
Avg EPS beat(12)-3.05%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)2
Avg Revenue beat(2)5.08%
Min Revenue beat(2)3.45%
Max Revenue beat(2)6.72%
Revenue beat(4)4
Avg Revenue beat(4)3.8%
Min Revenue beat(4)1.09%
Max Revenue beat(4)6.72%
Revenue beat(8)5
Avg Revenue beat(8)1.4%
Revenue beat(12)7
Avg Revenue beat(12)0.24%
Revenue beat(16)9
Avg Revenue beat(16)0.48%
PT rev (1m)2.72%
PT rev (3m)19.27%
EPS NQ rev (1m)0.49%
EPS NQ rev (3m)0.52%
EPS NY rev (1m)0.12%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)0.22%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.28%
Valuation
Industry RankSector Rank
PE 14.89
Fwd PE 12.63
P/S 4.12
P/FCF 16.58
P/OCF 15.86
P/B 4.27
P/tB 4.54
EV/EBITDA 12.17
EPS(TTM)6.79
EY6.72%
EPS(NY)8.01
Fwd EY7.92%
FCF(TTM)6.1
FCFY6.03%
OCF(TTM)6.37
OCFY6.31%
SpS24.52
BVpS23.69
TBVpS22.29
PEG (NY)0.83
PEG (5Y)N/A
Graham Number60.16
Profitability
Industry RankSector Rank
ROA 18.78%
ROE 25.55%
ROCE 25.17%
ROIC 19.88%
ROICexc 48.14%
ROICexgc 55.55%
OM 26.1%
PM (TTM) 24.69%
GM 93.47%
FCFM 24.87%
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexgc growth 3Y-34.92%
ROICexgc growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score7
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.02
Cap/Depr 59.08%
Cap/Sales 1.13%
Interest Coverage 250
Cash Conversion 92.81%
Profit Quality 100.71%
Current Ratio 3.2
Quick Ratio 3.13
Altman-Z 9.02
F-Score7
WACC12.31%
ROIC/WACC1.62
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.39%
EPS 3Y34.67%
EPS 5YN/A
EPS Q2Q%25.87%
EPS Next Y17.92%
EPS Next 2Y14.96%
EPS Next 3Y14.58%
EPS Next 5Y-7.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.84%
Revenue Next Year10.92%
Revenue Next 2Y10.4%
Revenue Next 3Y7.93%
Revenue Next 5Y-1.16%
EBIT growth 1Y6374.01%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year366.76%
EBIT Next 3Y85.64%
EBIT Next 5Y26.81%
FCF growth 1Y106.03%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y97.88%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%

INCYTE CORP / INCY FAQ

What is the fundamental rating for INCY stock?

ChartMill assigns a fundamental rating of 6 / 10 to INCY.


What is the valuation status of INCYTE CORP (INCY) stock?

ChartMill assigns a valuation rating of 8 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.


How profitable is INCYTE CORP (INCY) stock?

INCYTE CORP (INCY) has a profitability rating of 7 / 10.


How financially healthy is INCYTE CORP?

The financial health rating of INCYTE CORP (INCY) is 7 / 10.


Can you provide the expected EPS growth for INCY stock?

The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 17.92% in the next year.